Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.

Abstract

In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine) who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.

Keywords: Immune Thrombocytopenic Purpura; Rechallenge; mRNA SARS Cov2 vaccine.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • COVID-19 Vaccines / adverse effects
  • COVID-19*
  • Female
  • Humans
  • Purpura, Thrombocytopenic, Idiopathic* / etiology
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccines*
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines
  • Vaccines, Synthetic
  • mRNA Vaccines